Company intelligence / Profile preview

Syncromune

Fort Lauderdale, Florida, United Statessyncromune.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Syncromune’s lead programs are in Phase I clinical trials targeting metastatic solid tumors. The company’s SYNC-T and Syncrovax platforms combine partial tumor oncolysis with direct intratumoral delivery of multi-target biologics to synchronize antigen release and immune activation. Early results in mCRPC patients have been described as “powerful,” with a Q2 data presentation planned for their lead program.

Therapeutic areas: Oncology
Modalities: Intratumoral immunotherapyMulti-target biologic drugsOncolytic therapy (partial oncolysis)Antibody-based therapies (e.g., OX40 antibody)
Industry: Biotech

Drug pipeline

4 assets

SYNC-T

3 more assets in the full pipeline.

Partnerships

Eucure Biopharma Co., Ltd. / Biocytogen Pharmaceuticals – exclusive worldwide license agreement for YH002 OX40 antibody and two other active ingredients.

Beyond the preview

Go deeper on Syncromune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syncromune.